Comparative Pharmacology
Head-to-head clinical analysis: LO MINASTRIN FE versus LO OVRAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LO MINASTRIN FE versus LO OVRAL.
LO MINASTRIN FE vs LO/OVRAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone (progestin). Inhibits ovulation by suppressing gonadotropin release; increases viscosity of cervical mucus, inhibiting sperm penetration; alters endometrial lining, reducing implantation likelihood.
Combination estrogen-progestin oral contraceptive; suppresses gonadotropin release, primarily FSH and LH, inhibiting ovulation; increases viscosity of cervical mucus, impeding sperm penetration; alters endometrial receptivity.
1 tablet (1 mg norethindrone acetate/20 mcg ethinyl estradiol/ferrous fumarate 75 mg) orally once daily for 28 consecutive days.
One tablet (30 mcg ethinyl estradiol, 0.3 mg norgestrel) orally once daily for 28-day cycle (21 active, 7 placebo).
None Documented
None Documented
Norethindrone: 8-11 hours; ethinyl estradiol: 12-16 hours. Steady-state achieved after 5-7 days of dosing.
Norgestrel (levonorgestrel): 11-45 hours (mean ~24 hours); ethinyl estradiol: 7-21 hours (mean ~14 hours). Half-life increases slightly with repeated dosing due to saturable metabolism.
Renal: 40-50% as conjugated metabolites; fecal: 20-30% via biliary excretion; unchanged drug <1%.
Urine (50-60% as conjugated metabolites), feces (30-40% as metabolites), enterohepatic recirculation present.
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive